Young Wendy B.

Director Wendy B. Young buys 3,500 RAPP shares at $22.60; holdings rise 58.3% to 9,500 shares

Director Wendy B. Young purchased 3,500 shares at $22.60 on 2025-09-11, increasing her stake by 58.3% to 9,500 shares total. This open-market buy occurs at a price 2.6% below the current market price of $23.20, and 30.3% below the stock's 52-week high of $31.47. Notably, her prior buy at RAPP on 2025-03-12 exhibited strong 90-day performance (+28.9%), aligning with a perfect track record pattern on RAPP (1 of 1 prior buys well-timed at the 90-day mark). However, the company remains unprofitable with a full-year net income of $-26,732,000.00, and the stock has appreciated 49.3% over the past 30 days and 107.3% over 90 days — dynamics that context the timing and scale of this incremental accumulation within an already volatile trading environment.

Director Wendy B. Young buys 6,000 shares of RAPP at $10.21 as stock declines 65.7% from 52-week high.

Director Wendy B. Young purchased 6,000 shares of Rapport Therapeutics at $10.21 on 2025-03-12, establishing her first position in the company. The purchase occurs against a backdrop of significant downward momentum: the stock trades at $10.02, representing a -65.7% decline from its 52-week high of $29.23 and a -36.3% drop over the preceding 30 days. The company reported a full-year net income of $-17,537,000.00, indicating ongoing unprofitability. An insider director opening a position near current lows while the company remains unprofitable presents a mixed signal—the acquisition of equity stake during a depressed market period for the stock, coupled with substantial losses, warrants close monitoring of the company's path to profitability and near-term catalysts.